SRPT: Sarepta Therapeutics Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics, Inc. (SRPT) relies on ultra-precise cryo-logistics for the delivery of gene therapies, operating in a climate of fierce competition with global behemoths for dominance in the rare pathology niche. The fundamental P/S ratio allows for the timely detection of market euphoria, with the metric currently holding at 0.80. The company's monopoly status is secured by patents and FDA approval, which create insurmountable barriers to entry for new players.

SRPT sarepta.com Price-to-Revenue Ratio (07/04/2022 - 11/17/2026)

Metric breakdowns and analytics for Sarepta Therapeutics Inc (SRPT)

- stock quotes and analyst forecast:
- market capitalization information:
General company analysis:SRPT - Sarepta Therapeutics Inc
Signature product of Sarepta Therapeutics

The P/S multiple compares a business's market value to its generated revenue, allowing for an assessment of the value of each dollar of sales and determining the asset's degree of overboughtness. For Sarepta Therapeutics, Inc. (SRPT), with its monopoly on Duchenne therapy, the price/sales multiple reflects market expectations for the scaling of the Elevidys platform, turning local dips into an indicator of fundamental undervaluation while patent superiority persists.

Who Sarepta Therapeutics, Inc. competes with

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Twist Bioscience, Inc. (TWST)|Market Cap to Revenue 10x Genomics TXG|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio